CA2861668C - Stimulus-elicited genomic profile markers of a neurodegenerative condition - Google Patents
Stimulus-elicited genomic profile markers of a neurodegenerative condition Download PDFInfo
- Publication number
- CA2861668C CA2861668C CA2861668A CA2861668A CA2861668C CA 2861668 C CA2861668 C CA 2861668C CA 2861668 A CA2861668 A CA 2861668A CA 2861668 A CA2861668 A CA 2861668A CA 2861668 C CA2861668 C CA 2861668C
- Authority
- CA
- Canada
- Prior art keywords
- gene
- stimulus
- cell sample
- cells
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161543416P | 2011-10-05 | 2011-10-05 | |
| US61/543,416 | 2011-10-05 | ||
| PCT/US2012/059137 WO2013052922A1 (en) | 2011-10-05 | 2012-10-05 | Stimulus-elicited genomic profile markers of a neurodegenerative condition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2861668A1 CA2861668A1 (en) | 2013-04-11 |
| CA2861668C true CA2861668C (en) | 2021-09-07 |
Family
ID=47116384
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2861668A Active CA2861668C (en) | 2011-10-05 | 2012-10-05 | Stimulus-elicited genomic profile markers of a neurodegenerative condition |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20140235496A1 (https=) |
| EP (1) | EP2764120B1 (https=) |
| JP (2) | JP2014528247A (https=) |
| CA (1) | CA2861668C (https=) |
| WO (1) | WO2013052922A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2935266C (en) * | 2014-01-03 | 2022-02-01 | Blanchette Rockefeller Neurosciences Institute | Convergence of aggregation rate with validated peripheral diagnostics for alzheimer's disease |
| CN105353135A (zh) * | 2015-11-23 | 2016-02-24 | 中国人民解放军第三军医大学第一附属医院 | 阿尔茨海默病标志物的用途 |
| JP6694512B2 (ja) * | 2015-12-30 | 2020-05-13 | フジフィルム セルラー ダイナミクス，インコーポレイテッド | 幹細胞由来ヒト肝細胞を使用した微小組織形成 |
| US11415574B2 (en) | 2017-03-31 | 2022-08-16 | NeuroDiagnostics LLC | Lymphocyte-based morphometric test for alzheimer's disease |
| EP3787613B1 (en) * | 2018-04-30 | 2026-03-11 | Cedars-Sinai Medical Center | Pkc activation for use in treating early onset sporadic parkinson's disease |
| EP4262777A4 (en) * | 2020-12-16 | 2025-01-01 | Synaptogenix, Inc. | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS WITH PKC ACTIVATORS |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5976816A (en) | 1993-05-03 | 1999-11-02 | The United States Of America As Represented By The Department Of Health And Human Services | Cell tests for alzheimer's disease |
| US6300085B1 (en) | 1993-05-03 | 2001-10-09 | The United States Of America As Represented By The Department Of Health And Human Services | Diagnostic method for Alzheimer's disease |
| EP0890105B1 (en) * | 1996-03-29 | 2006-11-22 | The Trustees Of Boston University | Methods related to Alzheimer's disease for diagnosis, manufacture of medicaments and screening of substances and beta-amyloid related peptides |
| US6218122B1 (en) | 1998-06-19 | 2001-04-17 | Rosetta Inpharmatics, Inc. | Methods of monitoring disease states and therapies using gene expression profiles |
| EP1934618B1 (en) | 2005-10-11 | 2009-05-13 | Blanchette Rockefeller Neurosciences Institute | Alzheimer's disease-specific alterations of the erk1/erk2 phosphorylation ratio-alzheimer's disease-specific molecular biomarkers (adsmb) |
| US20080058396A1 (en) | 2006-07-28 | 2008-03-06 | Alkon Daniel L | Methods of stimulating cellular growth, synaptic remodelling and consolidation of long-term memory |
| US20100040584A1 (en) * | 2006-12-19 | 2010-02-18 | Children's Medical Center Corporation | Methods for promoting neovascularization |
| EP2669386A1 (en) * | 2008-07-28 | 2013-12-04 | Blanchette Rockefeller Neurosciences Institute | Stimulus-elicited genomic profile markers of alzheimer's disease |
| WO2010014585A1 (en) | 2008-07-28 | 2010-02-04 | Blanchette Rockefeller Neurosciences Institute | Pkc-activating compounds for the treatment of neurodegenerative diseases |
| KR101054725B1 (ko) * | 2008-07-31 | 2011-08-05 | 재단법인서울대학교산학협력재단 | 세포외기질 성분을 함유하는 노화조절용 조성물 및 이를이용한 노화세포의 노화조절방법 |
| US8658134B2 (en) * | 2009-10-02 | 2014-02-25 | Blanchette Rockefeller Neurosciences Institute | Fibroblast growth patterns for diagnosis of Alzheimer's disease |
-
2012
- 2012-10-05 CA CA2861668A patent/CA2861668C/en active Active
- 2012-10-05 US US14/346,822 patent/US20140235496A1/en active Pending
- 2012-10-05 WO PCT/US2012/059137 patent/WO2013052922A1/en not_active Ceased
- 2012-10-05 JP JP2014534811A patent/JP2014528247A/ja active Pending
- 2012-10-05 EP EP12780586.9A patent/EP2764120B1/en active Active
-
2017
- 2017-10-05 JP JP2017195118A patent/JP6636488B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP6636488B2 (ja) | 2020-01-29 |
| EP2764120A1 (en) | 2014-08-13 |
| EP2764120B1 (en) | 2020-06-10 |
| US20140235496A1 (en) | 2014-08-21 |
| JP2014528247A (ja) | 2014-10-27 |
| CA2861668A1 (en) | 2013-04-11 |
| JP2018046826A (ja) | 2018-03-29 |
| WO2013052922A1 (en) | 2013-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6636488B2 (ja) | 神経変性状態の刺激誘発性ゲノムプロファイルマーカー | |
| JP6404208B2 (ja) | 特発性肺線維症の予後予測、診断および処置の方法 | |
| Harris et al. | Monocyte chemotactic protein-1 inhibits chondrogenesis of synovial mesenchymal progenitor cells: an in vitro study | |
| EP2326729B1 (en) | Stimulus-elicited genomic profile markers of alzheimer's disease | |
| Aung et al. | MMP-9 expression is increased in B lymphocytes during multiple sclerosis exacerbation and is regulated by microRNA-320a | |
| JP5190654B2 (ja) | 分子マーカーを用いた間葉系幹細胞の識別方法及びその利用 | |
| Spielbauer et al. | Bacterial peptidoglycan signalling in microglia: Activation by MDP via the NF-κB/MAPK pathway | |
| KR20090098941A (ko) | 알츠하이머 질환의 검출 절차 및 방법 | |
| Nomair et al. | Circulating miR-146a-5p and miR-132–3p as potential diagnostic biomarkers in epilepsy | |
| US20120213769A1 (en) | Methods of diagnosing amyotrophic lateral sclerosis (als) | |
| Cosma et al. | Acute and chronic macrophage differentiation modulates TREM2 in a personalized Alzheimer’s patient-derived assay | |
| WO2018172540A1 (en) | Method to predict the progression of alzheimer's disease | |
| Gao et al. | The Screening of Piwi-Interacting RNA Biomarkers in Sporadic Parkinson's Disease | |
| Lopez-Rodriguez et al. | Microglial and Astrocyte priming in the APP/PS1 model of Alzheimer’s Disease: increased vulnerability to acute inflammation and cognitive deficits | |
| JP2022500087A (ja) | エピジェネティックマーカーを使用してせん妄危険性を検出するためのシステムおよび方法 | |
| Ritz et al. | Identification of inflammatory, metabolic, and cell survival pathways contributing to cerebral small vessel disease by postmortem gene expression microarray | |
| JP7489916B2 (ja) | Ｂｔｎｌ８を発現するｔ細胞の検出 | |
| US20090286238A1 (en) | Methods to Monitor, Diagnose and Identify Biomarkers for Psychotic Disorders | |
| US20090269770A1 (en) | Methods for evaluation prognosis and follow-up of drug treatment of psychiatric diseases or disorders | |
| KR101547307B1 (ko) | 뇌전증 진단용 바이오마커 | |
| EP1891241A2 (en) | Diagnostic and therapeutic target adarb2 proteins for neurodegenerative diseases | |
| JP2024136284A (ja) | うつ病の診断補助方法及び診断用キット | |
| Washington et al. | Peripheral markers of TBI and blood− brain barrier disruption | |
| Savinetti | Specific Signatures in Peripheral Blood Monocytes Stratify Multiple Sclerosis Patients Phenotypes | |
| KR20250163550A (ko) | 자폐증 진단 및 치료용 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20171002 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD Year of fee payment: 12 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240927 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240927 Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240927 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD Year of fee payment: 13 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250926 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250926 |